RILUZOLE (riluzole) by Italfarmaco Research is 12. Approved for amyotrophic lateral sclerosis (als) ( ). First approved in 2003.
Drug data last refreshed 18h ago
12.1 Mechanism of Action The mechanism by which riluzole exerts its therapeutic effects in patients with ALS is unknown. 12.2 Pharmacodynamics The clinical pharmacodynamics of riluzole has not been determined in humans. 12.3 Pharmacokinetics Table 2 displays the pharmacokinetic parameters of…
Worked on RILUZOLE at Italfarmaco Research? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis
Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in Chinese Healthy Subject
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder